	Application No.	Applicant(s)
Notice of Allowability	09/965,708 Examiner	HEIL ET AL. Art Unit
House of Anovasinty		Artonic
	Sonya Wright	1626
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not included not will be mailed in due course. THIS
1. This communication is responsive to		
2. The allowed claim(s) is/are 1-6 and 9-12, now claims 1-10 respectively.		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 0204 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Da 08), 7. ☑ Examiner's Amendo	te

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in telephone interviews with Mrs. Susan Pellegrino on February 18, 2004 and February 23, 2004.

The application has been amended as follows:

In claim 6, page 7, line 3, after "represents a suitable leaving group" insert --wherein the suitable leaving group is halogen--.

In claim 9, line 1, delete "composition" and insert –formulation--.

In claim 12, line 4, delete "autoimmune diseases,".

STATEMENT OF REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The instant claims are drawn to methanesulfonamide compounds wherein the "A" variable has been limited to oxygen. The closest prior art of record, JP 03056431, teaches methanesulfonamide compounds wherein the moiety corresponding to the "A" variable in the instant claims is NH. The instant claims are patentable over JP 03056431 because JP 03056431 neither teaches nor suggests oxygen for the "A" variable.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably Application/Control Number: 09/965,708

Art Unit: 1626

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sonya Wright, whose telephone number is (703) 308-4539. The examiner can normally be reached on Monday-Friday from 8:00 AM - 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (703) 308-4537. The Unofficial fax phone number for this Group is (703) 308-7922. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by

Art Unit: 1626

the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-1235.

Joseph K. McKane

Supervisory Patent Examiner

Group 1600

Sonya Wright

February 19, 2004